GSK-3 inhibitors and their potential in the treatment of Alzheimer’s disease

Bibliography

• DOBLE BW, WOODGETT JR: GSK3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. (2003) 116\(Pt.7):1175–1186.
   Google Scholar
• LUCAS JJ, HERNANDEZ F, GOMEZ-RAMOS P et al.: Decreased nuclear 0-catenin, tau hyperphosphorylation and neurodegeneration in GSK-313 conditional transgenic mice. EMBO J. (2001) 20(1-2):27–39.
   PubMedGoogle Scholar
• HERNANDEZ F, BORRELL J, GUAZA C, AVILA J, LUCAS JJ: Spatial learning deficit in transgenic mice that conditionally overexpress GSK-313 in the brain but do not form tau filaments. Neurochem . (2002) 83(6):1529–1533.
   PubMedGoogle Scholar
• ANNAERT W, DE STROOPER B: A cell biological perspective on Alzheimer's disease. Annu. Rev. Cell Dev. Biol. (2002) 18:25–51.
   PubMedGoogle Scholar
• BHAT RV BUDD HAEBERLEIN SL, AVILA J: Glycogen synthase kinase 3: a drug target for CNS therapies. Neurochem. (2004) 89(6):1313–1317.
   PubMedGoogle Scholar
• PEREZ M, HERNANDEZ F, LIM F, DIAZ-NIDO J, AVILA J: Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. Alzheimers Dis. (2003) 5(4):301–308.
   PubMedGoogle Scholar
• NOBLE W, PLANEL E, ZEHR C et al.: Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl Acad. Sci. USA (2005) 102(19):6990–6995.
   PubMed Web of Science ®Google Scholar
• SANTACRUZ K, LEWIS J, SPIRES T et al.: Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 309(5733):476–481.
   PubMed Web of Science ®Google Scholar
• SUN X, SATO S, MURAYAMA 0 et al.: Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci. Lett. (2002) 321(1–2):61–64.
   Google Scholar
• PHIEL CJ, WILSON CA, LEE VM, KLEIN PS: GSK-3a regulates production of Alzheimer's disease amyloid-B peptides. Nature (2003) 423(6938):435–439.
   PubMed Web of Science ®Google Scholar
• LEE MS, KAO SC, LEMERE CA et ell.: APP processing is regulated by cytoplasmic phosphorylation. J. Cell Biol. (2003) 163(1):83–95.
   Google Scholar
• RYDER J, SU Y, LIU F et al.: Divergent roles of GSK3 and CDK5 in APP processing. Biochem. Biophys. Res. Commun. (2003) 312(4):922–929.
   PubMedGoogle Scholar
• SU Y, RYDER J, LI B et al.: Lithium, a common drug for bipolar disorder treatment, regulates amyloid-B precursor protein processing. Biochemistry (2004) 43(22):6899–6908.
   PubMed Web of Science ®Google Scholar
• BAKI L, SHIOI J, WEN P et aL: PS1 activates PI3K thus inhibiting GSK3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J. (2004) 23(13):2586–2596.
   PubMed Web of Science ®Google Scholar
• TAKASHIMA A, MURAYAMA M, MURAYAMA 0 et al.: Presenilin 1 associates with glycogen synthase kinase-30 and its substrate tau. Proc. Nail. Acad. Sci. USA (1998) 95(10:9637–9641.
   Google Scholar
• RYDER J, SU Y,NI B: Akt/GSK30 serine/ threonine kinases: evidence for a signalling pathway mediated by familial Alzheimer's disease mutations. Cell. Signal. (2004) 16(2):187–200.
   PubMedGoogle Scholar
• MEIJER L, FLAJOLET M, GREENGARD P: Pharmacological inhibitors of glycogen synthase kinase 3. Trends PharmacoL Sci. (2004) 25(9):471–480.
   PubMed Web of Science ®Google Scholar
• COHEN P, GOEDERT M: GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. (2004) 3(6):479–487.
   PubMed Web of Science ®Google Scholar
• WAGMAN AS, JOHNSON KW, BUSSIERE DE: Discovery and development of GSK3 inhibitors for the treatment of Type 2 diabetes. Curr. Pharm. Des. (2004) 10(10):1105–1137.
   PubMedGoogle Scholar
• COGHLAN MP, CULBERT AA, CROSS DA et al.: Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. (2000) 7(10):793–803.
   PubMedGoogle Scholar
• CROSS DA, CULBERT AA, CHALMERS KA et al.: Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J. Neurochem. (2001) 77(1):94–102.
   PubMed Web of Science ®Google Scholar
• FACCI L, STEVENS DA, SKAPER SD: Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity. Neuroreport (2003) 14(11):1467–1470.
   PubMedGoogle Scholar
• BERTRAND JA, THIEFFINE S, VULPETTI A et al.: Structural characterization of the GSK-30 active site using selective and non-selective ATP-mimetic inhibitors. J. Md. Bid (2003) 333(2):393–407.
   PubMed Web of Science ®Google Scholar
• SMITH DG, BUFFET M, FENWICK AE et al.: 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK3). Bioorg. Med. Chem. Lett. (2001) 11(5):635–639.
   PubMedGoogle Scholar
• ENGLER TA, HENRY JR, MALHOTRA S et aL: Substituted 3-imiciazo [1,2-a] pyriclin-3-yl- 4-(1,2,3,4-tetrahydro41,41diazepino-l6,7,1-hilindo1-7-yhpyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3. J. Med. Chem. (2004) 47(16):3934–3937.
   PubMedGoogle Scholar
• ENGLER TA, MALHOTRA S, BURKHOLDER TP et aL: The development of potent and selective bisarylmaleimide GSK3 inhibitors. Bioorg. Med. Chem. Lett. (2005) 15(4):899–903.
   PubMedGoogle Scholar
• ZHANG HC, WHITE KB, YE H et aL: Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3. Bioorg. Med. Chem. Lett. (2003) 13(18):3049–3053.
   PubMedGoogle Scholar
• HERS I, TAVARE JM, DENTON RM: The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Lett. (1999) 460(3):433–436.
   PubMedGoogle Scholar
• KUO GH, PROUTY C, DEANGELIS A et al.: Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-30 inhibitors. J. Med. Chem. (2003) 46(19):4021–4031.
   PubMedGoogle Scholar
• SHEN L, PROUTY C, CONWAY BR et al.: Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthase kinase-30 (GSK-30) inhibitors. Bioorg Med. Chem. (2004) 12(5):1239–1255.
   PubMedGoogle Scholar
• ZHANG HC, YE H, CONWAY BR et aL: 3-(7-Azaindoly1)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3. Bioorg. Med. Chem. Lett. (2004) 14(12):3245–3250.
   PubMedGoogle Scholar
• O'NEILL DJ, SHEN L, PROUTY C et al.: Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-30 (GSK-30) inhibitors. Bioorg Med. Chem. (2004) 12(12):3167–3185.
   Google Scholar
• RING DB, JOHNSON KW, HENRIKSEN EJ et al.: Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes (2003) 52(3):588–595.
   PubMed Web of Science ®Google Scholar
• KELLY S, ZHAO H, HUA SUN G et aL: Glycogen synthase kinase 30 inhibitor Chir025 reduces neuronal death resulting from oxygen-glucose deprivation, glutamate excitotoxicity, and cerebral ischemia. Exp. Neurol. (2004) 188(2):378–386.
   PubMed Web of Science ®Google Scholar
• PEAT AJ, BOUCHERON JA, DICKERSON SH et al.: Novel pyrazolopyrimidine derivatives as GSK3 inhibitors. Bioorg. Med. Chem. Lett. (2004) 14(9):2121–2125.
   PubMedGoogle Scholar
• PEAT AJ, GARRIDO D, BOUCHERON JA et aL: Novel GSK3 inhibitors with improved cellular activity. Bioorg. Med. Chem. Lett. (2004) 14(9):2127–2130.
   PubMedGoogle Scholar
• MAEDA Y, NAKANO M, SATO H et aL: 4-Acylamino-6-arylfuropyrimidines:potent and selective glycogen synthase kinase-3 inhibitors. Bioorg. Med. Chem. Lett. (2004) 14(15):3907–3911.
   PubMedGoogle Scholar
• DING S, WU TY, BRINKER A et ell.: Synthetic small molecules that control stem cell fate. Proc. Natl Acad. Sci. USA (2003) 100(13):7632–7637.
   Google Scholar
• WITHERINGTON J, BORDAS GAIBA A et aL: 6-aryl-pyrazolo [3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK3). Bioorg. Med. Chem. Lett. (2003) 13(18):3055–3057.
   PubMedGoogle Scholar
• WITHERINGTON J, BORDAS GAIBA A et aL: 6-heteroaryl-pyrazolo [3,4-b]pyridines: potent and selective inhibitors of glycogen synthase kinase-3 (GSK3). Bioorg Med. Chem. Lett. (2003) 13(18):3059–3062.
   PubMedGoogle Scholar
• WITHERINGTON J, BORDAS GARLAND SL et al.: 5-aryl-pyrazolo [3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK3). Bioorg. Med. Chem. Lett. (2003) 13(9):1577–1580.
   Google Scholar
• WITHERINGTON J, BORDAS V, HAIGH D et al.: 5-Aryl-pyrazolo [3,4-pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK3). Bioorg. Med. Chem. Lett. (2003) 13(9):1581–1584.
   PubMedGoogle Scholar
• TAVARES FX, BOUCHERON JA, DICKERSON SH et al.: N-Phenyl-4-pyrazolo [1,5-b] pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy. J. Med. Chem. (2004) 47(19):4716–4730.
   PubMedGoogle Scholar
• BHAT R, XUE Y, BERG S et al.: Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. (2003) 278(40:45937–45945.
   PubMedGoogle Scholar
• GOULD TD, EINAT H, BHAT R, MANJI HK: AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J Neuropsychopharmacol. (2004) 7(4):387–390.
   PubMed Web of Science ®Google Scholar
• OLESEN PH, SORENSEN AR, URSO B et al.: Synthesis and in vitro characterization of 1-(4-aminofurazan-3-y1)-5-dialkylaminomethy1-11/41,2,3ltriazole-4-carboxylic acid derivatives. A new class of selective GSK3 inhibitors. J. Med. Chem. (2003) 46(15):3333–3341.
   Google Scholar
• LECLERC S, GARNIER M, HOESSEL R et al.: Indirubins inhibit glycogen synthase kinase-313 and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. (2001) 276(1):251–260.
   Google Scholar
• MEIJER L, SKALTSOUNIS AL, MAGIATIS P et al.: GSK3-selective inhibitors derived from Tyrian purple indirubins. Chem. Biol. (2003) 10(12):1255–1266.
   PubMedGoogle Scholar
• POLYCHRONOPOULOS P, MAGIATIS P, SKALTSOUNIS AL et al.: Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J. Med. Chem. (2004) 47(4):935–946.
   PubMed Web of Science ®Google Scholar
• LEOST M, SCHULTZ C, LINK A et al.: Paullones are potent inhibitors of glycogen synthase kinase-313 and cyclin-dependent kinase 5/p25. Eur. J. Biochem. (2000) 267(19):5983–5994.
   PubMedGoogle Scholar
• KNOCKAERT M, WIEKING K, SCHMITT S et aL: Intracellular targets of paullones. Identification following affinity purification on immobilized inhibitor. J. BioL Chem. (2002) 277(28):25493–25501.
   Google Scholar
• KUNICK C, LAUENROTH K, LEOST M, MEIJER L, LEMCKE T: 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-313. Bioorg. Med. Chem. Lett. (2004) 14(2):413–416.
   PubMedGoogle Scholar
• METTEY Y, GOMPEL M, THOMAS V et al.: Aloisines, a new family of CDK/ GSK3 inhibitors. SAP. study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J. Med. Chem. (2003) 46(2):222–236.
   Google Scholar
• NAERUM L, NORSKOV-LAURITSEN L, OLESEN PH: Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors. Bioorg. Med. Chem. Lett. (2002) 12(11):1525–1528.
   PubMedGoogle Scholar
• MEIJER L, THUNNISSEN AM, WHITE AW et al.: Inhibition of cyclin-dependent kinases, GSK-313 and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. (2000) 7(1):51–63.
   PubMedGoogle Scholar
• MARTINEZ A. ALONSO M, CASTRO A. PEREZ C, MORENO FJ: First non-ATP competitive glycogen synthase kinase 313 (GSK-313) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment ofAlzheimer's disease. J Med. Chem. (2002) 45(6):1292–1299.
   PubMed Web of Science ®Google Scholar
• LUNA-MEDINA R, CORTES -CANTELI M, ALONSO M et al.: Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor y activation. J. Biol. Chem. (2005) 280(22):21453–21462.
   PubMedGoogle Scholar
• CONDE S, PEREZ DI, MARTINEZ k PEREZ C, MORENO FJ: Thienyl and phenyl ct-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-313) from a library of compound searching. J. Med. Chem. (2003) 46(22):4631–4633.
   PubMedGoogle Scholar
• THOMAS GM, FRAMES, GOEDERT M et al.: A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and 13-catenin. FEBS Lett. (1999) 458(2):247–251.
   PubMedGoogle Scholar
• CULBERT AA, BROWN MJ, FRAME S et al.: GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and 13-catenin stabilisation without elevation of glycogen synthase activity. FEBS Lett. (2001) 507(3):288–294.
   PubMedGoogle Scholar
• LI B, RYDER J, SU Y et aL: FRAT1 peptide decreases Al3 production in swAPP(751) cells. FEBS Lett. (2003) 553(3):347–350.
   PubMedGoogle Scholar
• HEDGEPETH CM, DEARDORFF MA, RANKIN K, KLEIN PS: Regulation of glycogen synthase kinase 313 and downstream Wnt signaling by axin. MoL Cell. Biol. (1999) 19(10):7147–7157.
   PubMedGoogle Scholar
• FUJIMURO M, WU FY, APRHYS C et aL: A novel viral mechanism for dysregulation of13-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat. Med. (2003) 9(3):300–306.
   PubMedGoogle Scholar
• PLOTKIN B, KAIDANOVICH 0, TALIOR I, ELDAR-FINKELMAN H: Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. j PharmacoL Exp. Ther. (2003) 305(3):974–980.
   PubMed Web of Science ®Google Scholar
• KAIDANOVICH-BEILIN 0, MILMAN A, WEIZMAN A, PICK CG, ELDAR-FINKELMAN H: Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on 13-catenin in mouse hippocampus. Biol. Psychiatry (2004) 55(8):781–784.
   PubMed Web of Science ®Google Scholar
• YU JY TAYLOR J, DERUITER SL, VOJTEK AB, TURNER DL: Simultaneous inhibition of GSK-3u and GSK-313 using hairpin siRNA expression vectors. MoL Ther. (2003) 7(2):228–236.
   PubMedGoogle Scholar
• STANKUNAS K, BAYLE JH, GESTWICKI JE et al.: Conditional protein alleles using knockin mice and a chemical inducer of dimerization. Mol. Cell (2003) 12(6):1615–1624.
   PubMedGoogle Scholar
• HOEFLICH KP, LUO J, RUBIE EA et al.: Requirement for glycogen synthase kinase-313 in cell survival and NF-KB activation. Nature (2000) 406(6791):86–90.
   PubMed Web of Science ®Google Scholar
• O'BRIEN WT, HARPER AD, JOVE F et al.: Glycogen synthase kinase-313 haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. (2004) 24(30):6791–6798.
   Google Scholar
• MOON RT, KOHN AD, DE FERRARI GV, KAYKAS k WNT and 13-catenin signalling: diseases and therapies. Nat . Rev. Genet. (2004) 5(9):691–701.
   PubMed Web of Science ®Google Scholar
• FUENTEALBA RA, FARIAS G, SCHEU J et al.: Signal transduction during amyloid-13-peptide neurotoxicity: role in Alzheimer's disease. Brain Res. Brain Res. Rev. (2004) 47(1-3):275–289.
   PubMedGoogle Scholar
• DE CRAENE B, VAN ROY F, BERX G: Unraveling signalling cascades for the Snail family of transcription factors. Cell. Signal. (2005) 17(5):535–547.
   PubMedGoogle Scholar
• SCHLESSINGER K, HALL k GSK-30 sets Snail's pace. Nat. Cell Biol. (2004) 6(10):913–915.
   PubMedGoogle Scholar
• COHEN Y, CHETRIT A. COHEN Y, SIROTA P, MODAN B: Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment. Med. Oncol (1998) 15(1):32–36.
   PubMedGoogle Scholar
• MAZOR M, KAWANO Y, ZHU H, WAXMAN J, KYPTA RM: Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene (2004) 23(47):7882–7892.
   PubMedGoogle Scholar
• OUGOLKOV AV, FERNANDEZ -ZAPICO ME, SAVOY DN, URRUTIA RA, BILLADEAU DD: Glycogen synthase kinase-30 participates in nuclear factor KB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. (2005) 65(6):2076–2081.
   PubMedGoogle Scholar
• SHAKOORI A, OUGOLKOV A, YU ZW et al.: Deregulated GSK-30 activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem. Biophys. Res. Commun. (2005) 334(4):1365–1373.
   PubMed Web of Science ®Google Scholar